Company Overview and News


Add OSE
to your dashboard

Headline News

OSE Immunotherapeutics, MSK Partner on Anticancer IL-7R mAb

2017-06-13 genengnews
OSE Immunotherapeutics and Memorial Sloan Kettering Cancer Center (MSK) signed a multi-year agreement to support ongoing research with the French firm’s humanized monoclonal antibody (mAb) OSE-703 (Effi-3). The antibody targets the alpha chain of the interleukin-7 receptor (CD127).

Servier Pays OSE Immunotherapeutics €10.25M for Option to IL-7 Antagonist

2016-12-28 genengnews
Servier is paying OSE Immunotherapeutics €10.25 million ($10.71 million) for an option to license exclusive worldwide rights to the latter’s interleukin-7 receptor antagonist, Effi-7. The humanized monoclonal antibody targets the CD127 receptor, and is currently in preclinical development for the treatment of ulcerative colitis.

Bear of the Day: Macys (M)

2016-06-01 zacks
Despite low gas prices and improving labor market, consumers remain reluctant to spend much. Further, their rising preference for online shopping is adding to the headwinds for traditional department store operators like Macy’s (M - Analyst Report) . The company reported its worst quarterly results since 2009 and also slashed guidance for the current year, sending shares sharply lower after the report.